Presentation is loading. Please wait.

Presentation is loading. Please wait.

Class I Medical Therapies for CAD and PAD

Published byViolet Goodman Modified over 6 years ago

Similar presentations

Presentation on theme: "Class I Medical Therapies for CAD and PAD"— Presentation transcript:

1 Class I Medical Therapies for CAD and PAD
Aspirin alone DAPT after PCI or ACS Statin therapy Anti-HTN therapy Tobacco cessation/avoidance Diabetes management Influenza Vaccine Home-based exercise Cardiac Rehabilitation after ACS, CABG, or PCI Weight loss Aspirin alone or Clopidogrel alone Statin therapy Anti-HTN therapy Tobacco cessation/avoidance Diabetes management Influenza vaccine Supervised exercise program JACC 2017;69:e JACC 2011;58:

2 COMPASS: Rivaroxaban in stable CAD and PAD
All Patients PAD Patients Only NEJM 2017; 377: Lancet 2017; 391:

3 Exercise for PAD vs. Cardiac Rehabilitation
JACC 2017;69:e71-126

Download ppt "Class I Medical Therapies for CAD and PAD"

Similar presentations

What Have We Learned from the CRUSADE Registry

What Have We Learned from the CRUSADE Registry
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Technology and Expenditure Growth in Health Care Amitabh Chandra HARVARD UNIVERSITY.

Technology and Expenditure Growth in Health Care Amitabh Chandra HARVARD UNIVERSITY.
Cardiac Issues With Noncardiac Surgery Joseph F. Winget, MD FACC Clinical Assistant Professor University of Vermont Medical School Champlain Valley Cardiovascular.

Cardiac Issues With Noncardiac Surgery Joseph F. Winget, MD FACC Clinical Assistant Professor University of Vermont Medical School Champlain Valley Cardiovascular.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.

© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.
Redwood Community Care Organization Data Capture for ACO Quality Measures.

Redwood Community Care Organization Data Capture for ACO Quality Measures.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Data Input Manual ACO Specific Quality Measures. Table of Contents Selection of Attributed ACO Patient…………………………………………………………...…….1 Section of Proper.

Data Input Manual ACO Specific Quality Measures. Table of Contents Selection of Attributed ACO Patient…………………………………………………………...…….1 Section of Proper.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,

Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.

Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.

C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Claims-Based Quality Measures CMS Physician Group Practice Demonstration Project Chealsea Nather 26 January 2005.

Claims-Based Quality Measures CMS Physician Group Practice Demonstration Project Chealsea Nather 26 January 2005.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.

BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.

CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.

Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.

Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.

Similar presentations

Ads by Google